Search
for
Sort by
Research 25
- Redox-Modulatory and MET-Inhibitory Triad: Synergistic Cytotoxicity of L-cysteine, NAC, and MET Inhibition in Cervical Cancer Cells
- Toward a Unifying Hypothesis for Redesigned Lipid Catabolism as a Clinical Target in Advanced, Treatment-Resistant Carcinomas
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Chaperones as thermodynamic sensors
- Management of Toxicities of Targeted Therapies
- Targeting receptor–regulator interactions
- Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Drug Repositioning: New Opportunities for Older Drugs
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Index
- Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity against H-1975 Cell Lines
- Clinical Value Analysis of Pemetrexed Combined with Cisplatin in the Treatment of Non-Small Cell Lung Cancer
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Cancer-Related Alopecia: From Etiologies to Global Management
- Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
- Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
- CAQ Corner: Basic concepts of transplant immunology